8 completed, 8 recruiting, 7 active not recruiting, 3 not yet recruiting. 17 Phase 2, 11 Phase 3, 3 Phase 1, 1 Not applicable, 1 Phase 4.
Follow Immunoglobulin A Nephropathy: new trials by email Literature Review of Immunoglobulin A Nephropathy trials Research Report on Immunoglobulin A Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab - Immunoglobulin A Nephropathy | Phase 2 | Not yet recruiting | Biogen | 25 | 2026-11-16 | 2026-10-22 |
| A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe Povetacicept, Sibeprenlimab - Immunoglobulin A Nephropathy | Phase 3 | Not yet recruiting | Vertex Pharmaceuticals Incorporated | 40 | 2026-10-23 | 2026-10-22 |
| A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy Povetacicept - Immunoglobulin A Nephropathy | Phase 3 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 605 | 2026-09-17 | 2026-10-19 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN Drug: Atrasentan - Berger Disease, Bergers Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 28 | 2026-08-06 | 2026-10-15 |
| A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. MIL116, Matching Placebo - Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 130 | 2026-02-05 | 2026-04-13 |
| Study of Ravulizumab in Pediatric Participants With Primary IgAN Ravulizumab - IgAN, IgAVN | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 36 | 2025-06-14 | 2026-07-30 |
| A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US No intervention, Other treatment, Iptacopan - Immunoglobulin A Nephropathy | Recruiting | Novartis Pharmaceuticals | 300 | 2025-03-04 | 2025-06-17 | |
| Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN Iptacopan - Glomerulonephritis, IGA, Immunoglobulin A Nephropathy | Phase 2 | Recruiting | Novartis Pharmaceuticals | 20 | 2025-02-21 | 2026-07-29 |
| A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy HS-10390, Irbesartan - Immunoglobulin a Nephropathy | Phase 2 | Not yet recruiting | Hansoh BioMedical R&D Company | 90 | 2024-11-01 | 2024-10-10 |
| Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) Povetacicept, Placebo (matched to Povetacicept) - Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Alpine Immune Sciences Inc, A Subsidiary of Vertex | 605 | 2024-08-30 | 2026-05-15 |
| Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Ravulizumab, Placebo - Immunoglobulin A Nephropathy, IgAN | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 584 | 2024-03-29 | 2026-10-02 |
| Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy Atrasentan, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 2 | Completed | Novartis Pharmaceuticals | 54 | 2023-07-20 | 2026-07-20 |
| A Study of Zigakibart in Adults With IgA Nephropathy BION-1301, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 383 | 2023-07-06 | 2026-04-01 |
| A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN Sparsentan - Immunoglobulin A Nephropathy | Phase 2 | Completed | Travere Therapeutics, Inc. | 48 | 2023-05-19 | 2025-11-20 |
| Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Corticosteroid, Renin-angiotensin sytem blockers, Sodium-glucose cotransporter 2 inhibitor - Glomerulonephritis, Immunoglobulin A Nephropathy | Phase 4 | Recruiting | Fondazione Schena | 878 | 2023-05-01 | 2025-04-02 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Sibeprenlimab 400 mg s.c. Q4weeks - Immunoglobulin A Nephropathy | Phase 2 / Phase 3 | Enrolling by invitation | Otsuka Pharmaceutical Development & Commercialization, Inc. | 600 | 2022-04-05 | 2026-05-05 |
| Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) Sibeprenlimab 400 mg, Placebo - Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 530 | 2022-03-15 | 2026-07-14 |
| Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) BCX9930 - Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy | Phase 2 | Terminated | BioCryst Pharmaceuticals | 2 | 2022-02-18 | 2024-05-02 |
| Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy | Completed | Travere Therapeutics, Inc. | 487 | 2022-02-05 | 2024-02-21 |
Showing 20 of 33. Sign in to see all of them.
Glomerulonephritis, IGA (33) · Glomerulonephritis (9) · Kidney Diseases (6) · Renal Insufficiency, Chronic (5) · Urologic Diseases (4) · Glomerulosclerosis, Focal Segmental (3) · Lupus Nephritis (3) · Proteinuria (3) · Autoimmune Diseases (2) · Glomerulonephritis, Membranous (2) · IgA Vasculitis (2) · Immune System Diseases (2) · Nephritis, Hereditary (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Churg-Strauss Syndrome (1)
Female Urogenital Diseases (33) · Female Urogenital Diseases and Pregnancy Complications (33) · Male Urogenital Diseases (33) · Urogenital Diseases (33) · Nephritis (32) · Autoimmune Diseases (31) · Immune System Diseases (31) · Urologic Diseases (29) · Kidney Diseases (27) · Glomerulonephritis (24) · Pathological Conditions, Signs and Symptoms (8) · Pathologic Processes (7) · Skin and Connective Tissue Diseases (7) · Connective Tissue Diseases (6) · Chronic Disease (5)
Atrasentan (5) · sparsentan (4) · ravulizumab (3) · Irbesartan (2) · dapagliflozin (2) · iptacopan (2) · Adrenal Cortex Hormones (1) · Canagliflozin (1) · Fish Oils (1) · Lisinopril (1) · Losartan (1) · Methylprednisolone Hemisuccinate (1) · Prednisolone (1) · Ramipril (1) · Sodium-Glucose Transporter 2 Inhibitors (1)
Novartis Pharmaceuticals (7) · Alexion Pharmaceuticals, Inc. (4) · Otsuka Pharmaceutical Development & Commercialization, Inc. (4) · Travere Therapeutics, Inc. (4) · Vertex Pharmaceuticals Incorporated (2) · Alpine Immune Sciences Inc, A Subsidiary of Vertex (1) · Alpine Immune Sciences, Inc. (1) · Amgen (1) · Baxalta now part of Shire (1) · Beijing Mabworks Biotech Co., Ltd. (1) · BioCryst Pharmaceuticals (1) · Biogen (1) · Fondazione Schena (1) · Hansoh BioMedical R&D Company (1) · Medical University of Warsaw (1)
United States (24) · Spain (17) · South Korea (15) · Italy (14) · United Kingdom (14) · Australia (13) · Taiwan (12) · China (11) · Germany (11) · France (10) · Japan (9) · Poland (9) · Brazil (8) · Canada (8) · Hong Kong (8)
Radko Komers, MD, PhD (3) · Angela M Zivkovic, PhD (1) · Asher Schachter, M.D. (1) · Bruce D Hammock, PhD (1) · Carla M Nester, MD, MSA, FASN (1) · Chee Kay Cheung, MBChB PhD (1) · Esther Yoon, MD (1) · Francesco P Schena (1) · J. Bruce German, PhD (1) · Leah Conley, MBA (1)
PMID 38299639, PMID 37254256, PMID 37528520, PMID 39455063, PMID 39899371, PMID 40465397, PMID 40938675, PMID 41442197, PMID 42275148, PMID 42384439, PMID 15851648, PMID 17533019, PMID 17978307, PMID 19571790, PMID 19571791, PMID 21606384, PMID 21852672, PMID 24029421, PMID 25018935, PMID 25585823, PMID 26630142, PMID 26672987, PMID 28341274, PMID 28763548, PMID 30177015, PMID 32409237, PMID 32889014, PMID 32970396, PMID 32998816, PMID 33023926, PMID 35570983, PMID 37015244, PMID 37772889, PMID 37916620, PMID 37931634, PMID 38059359, PMID 38724717, PMID 38770818, PMID 39460694, PMID 40482854, PMID 41211929, PMID 41426046, PMID 41428405, PMID 41904616, PMID 42205925, PMID 42242268, PMID 42633049, PMID 9100040
2023 (2), 2014 (1), 2015 (1), 2017 (1), 2018 (1), 2019 (1), 2025 (1)